Lymphoma is a clinically and biologically heterogeneous disease. Next-generation
sequencing (NGS) has expanded our understanding of this heterogeneity at the genetic …

Darwinian selection is also applicable when antibiotics, the immune system or other host
factors shape the repertoire of microorganisms, and similarly, clonal selection is the hallmark …

ALK-positive anaplastic large cell lymphoma (ALCL) represents a subset of non-Hodgkin's
lymphoma that is treated with crizotinib, a dual ALK/MET inhibitor. Despite the remarkable …

As a potent and selective drug, brigatinib exhibits high efficacy against wild‐type and mutant
anaplastic lymphoma kinase (ALK) proteins to treat non–small cell lung cancer. In this work …

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of lymphoid malignancies
accounting for a significant portion of cancers occurring in children, adolescents, and young …

Introduction Anaplastic lymphoma kinase-positive (ALK+) anaplastic large cell lymphoma
(ALCL) is a type of non-Hodgkin lymphoma, which has strong expression of cluster of …

ALK-positive anaplastic large cell lymphoma (ALCL) represents a subset of non-Hodgkin's
lymphoma that is treated with crizo-tinib, a dual ALK/MET inhibitor. Despite the remarkable …

Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of clinically aggressive
malignancies derived from mature (post-thymic) T-cells or Natural Killer cells, which …

Los linfomas constituyen un grupo heterogéneo de entidades linfoproliferatívas con
diversos patrones de comportamiento clínico, biológico y de respuesta al tratamiento. La …

L'oncogène ALK (Anaplastic Lymphoma Kinase) est une tyrosine kinase constitutivement
active, impliquée dans divers cancers, tels que les lymphomes anaplasiques à grandes …